Mitazalimab
Cat. No.: IBDI-431986
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.
Product Details
| Target |
TNF Receptor |
| Synonyms |
ADC-1013, JNJ-64457107 |
| SMILES |
[Mitazalimab] |
Storage & Handling
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
